GLP-1 medications typically achieve this threshold within 8 to 12 weeks, though individual timelines vary
NICE guidance recommends regular monitoring of patients on GLP-1 receptor agonists, including assessment of gastrointestinal tolerability, weight changes, and glycaemic control
When asked about the therapeutic advantages of targeting the brains GLP-1 system, Trapp shares promising findings
This enhancement of neurotrophic signalling leads to rapid improvements in mood and cognitive flexibility, aligning with the neuroplasticity-based hypothesis of MDD, which posits that MDD arises from widespread deficits in neuronal plasticity and connectivity [229]
GLP-1 receptors are expressed both centrally (in the brain) and peripherally (in immune cells, the gut, and metabolic tissues)